Unicycive Therapeutics, Inc. — Form 8-K Summary
Business Context and Reporting Period
Unicycive Therapeutics, Inc. filed a Form 8-K regarding Nasdaq listing compliance notices received on September 19, 2023. The report was signed on September 25, 2023. The company’s common stock trades on the Nasdaq Capital Market under the symbol UNCY.
Financial Metrics and Liquidity
This filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other operating financial metrics.
Material Changes Versus the Prior Comparable Period
- Nasdaq notified the company that its common stock had closed below the $35 million minimum market value requirement for 30 consecutive business days under Nasdaq Listing Rule 5550(b)(2).
- Nasdaq separately notified the company that its common stock had closed below the $1.00 minimum bid price requirement for 30 consecutive business days under Nasdaq Listing Rule 5550(a)(2).
- Both notices were received on September 19, 2023 and had no immediate effect on the listing or trading of the common stock.
Outlook, Risks, Contingencies, and Unusual Items
- The company received an initial 180-calendar-day compliance period for both deficiencies, ending March 18, 2024.
- To regain compliance with the minimum bid price requirement, the stock’s closing bid price must be at least $1.00 for a minimum of 10 consecutive business days during the compliance period.
- If the company fails to regain compliance with the market value requirement by March 18, 2024, Nasdaq may issue a delisting notice.
- The company may qualify for a second 180-calendar-day period for the bid price deficiency, subject to Nasdaq’s requirements.
- If Nasdaq issues a delisting determination, the company may appeal to a Nasdaq Hearings Panel.
- Management stated that it intends to monitor the stock’s market value and evaluate available options to regain compliance, but cautioned that there can be no assurance of regaining or maintaining compliance with Nasdaq listing requirements.
Key Facts for Investors to Verify
- Whether UNCY regained compliance with the $35 million minimum market value requirement by March 18, 2024.
- Whether UNCY regained compliance with the $1.00 minimum bid price requirement, including any second compliance period.
- Any subsequent Nasdaq delisting notice, appeal, hearing, or remedial corporate action.
- The company’s financial condition and funding needs, which are not addressed in this filing.